McCarthy, Anne Marie
Fernandez Perez, Claudia
Beidas, Rinad S.
Bekelman, Justin E.
Blumenthal, Daniel
Mack, Elizabeth
Bauer, Anna-Marika
Ehsan, Sarah
Conant, Emily F.
Wheeler, Bernadette C.
Guerra, Carmen E.
Nunes, Linda W.
Gabriel, Peter
Doucette, Abigail
Wileyto, E. Paul
Buttenheim, Alison M.
Asch, David A.
Rendle, Katharine A.
Shelton, Rachel C.
Fayanju, Oluwadamilola M.
Ware, Sue
Plag, Martina
Hyland, Steven
Gionta, Tracy
Shulman, Lawrence N.
Schnoll, Robert
Funding for this research was provided by:
National Cancer Institute (P50 CA244690)
Article History
Received: 19 September 2023
Accepted: 14 November 2023
First Online: 24 November 2023
Declarations
:
: This trial was approved by the University of Pennsylvania Institutional Review Board.
: Not applicable.
: Dr. Beidas is the principal at Implementation Science & Practice, LLC. She receives royalties from Oxford University Press, consulting fees from United Behavioral Health and OptumLabs, and serves on the advisory boards for Optum Behavioral Health, AIM Youth Mental Health Foundation, and the Klingenstein Third Generation Foundation outside of the submitted work. She is also an associate editor for <i>Implementation Science</i>. Dr. Bekelman reports grants from AstraZeneca, Emerson Collective, Loxo@Lilly, and Gilead and personal fees from Reimagine Care, Healthcare Foundry, and AstraZeneca, outside the submitted work. Dr. Conant reports grant funding from OM1 and iCAD, Inc., and serves on advisory panels for Hologic, Inc., and iCAD, Inc., all outside of the submitted work. Dr. Asch is a partner at VAL Health and has received grants from UnitedHealth Group and personal fees from Deloitte, MARS Veterinary Group, and Boehringer Ingelheim. Dr. Rendle reports receiving grants from Pfizer and AstraZeneca paid to her institution, personal fees from Merck for serving as a scientific consultant, and honoraria and travel paid as an invited speaker from MJH Life Sciences outside the submitted work.